Korro Bio, Inc. (KRRO): Submission of Matters to a Vote of Security Holders
Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001703647 NASDAQ 0001703647 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event report ed): J
How this was made
The 30-second read
Why it matters
The disclosure confirms routine governance actions: election of two Class I directors, a non-binding advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor for 2026.
Market read
Traders may treat this as a low-impact corporate housekeeping update unless it coincides with other news (e.g., financing, clinical readouts, or regulatory actions).
What to watch
Vote counts (withheld/broker non-votes) can hint at shareholder engagement, but the filing does not indicate contested outcomes or material governance disputes.
Background
The SEC 8-K Item 5.07 summarizes matters voted on at Korro Bio’s June 10, 2026 annual meeting of stockholders.
Ticker impact
Korro Bio’s 8-K reports results of its June 10, 2026 annual meeting, including election of two Class I directors and advisory executive comp approval.
Low likelihood of a sustained move; any reaction is likely brief unless tied to other contemporaneous catalysts.
The filing provides vote tallies for director elections, non-binding executive compensation, and ratification of auditors—no new clinical, financial, or regulatory developments are disclosed.
Market effects
No direct read-across to biotech sector fundamentals; governance vote outcomes are company-specific.
None indicated; filing is not tied to regional operations or macro events.
None indicated; no international transaction or cross-border regulatory action mentioned.
Counterpoint
If investors were concerned about board stability or auditor continuity, the ratification and director elections could reduce uncertainty, but the disclosure still lacks new operating information.
Key entities
- issuerKorro Bio, Inc.
NASDAQ-listed company filing the 8-K with annual meeting vote results.
- director_candidateNessan Bermingham
Elected as Class I director for a three-year term (vote tallies disclosed).
- director_candidateRachel Meyers
Elected as Class I director for a three-year term (vote tallies disclosed).
- auditorErnst & Young LLP
Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.
